Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody

Nuclear Medicine and Biology

Volumn 40, Issue 1, 2013, Pages 52-59

  Pruszynski, Marek ^a   Koumarianou, Eftychia ^a   Vaidyanathan, Ganesan ^a   Revets, Hilde ^b   Devoogdt, Nick ^c   Lahoutte, Tony ^c   Zalutsky, Michael R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b ABLYNX NV   (Belgium)

^c VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Breast cancer; HER2; IB Mal d GEEEK; Nanobody; Radioiodination; VHH

Indexed keywords

5F7GGC NANOBODY; ABLYNX; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; IODINE 125; IODINE 131; IODOBENZOYL MALEIMIDO DEXTRO GEEEK I 131; NANOBODY; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; ANTIBODY SPECIFICITY; ARTICLE; BREAST CARCINOMA; CARCINOMA CELL; CELL STRAIN; CELL STRAIN BT474M1; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG SYNTHESIS; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; HUMAN; HUMAN CELL; IMMUNOASSAY; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; KIDNEY PARENCHYMA; METABOLIC RATE; MOUSE; NONHUMAN; PLASMA CLEARANCE; PROTEIN EXPRESSION; PROTEIN TARGETING; RADIOCHEMISTRY; RADIOIODINATION; TISSUE DISTRIBUTION; TUMOR XENOGRAFT;

ANIMALS; ANTIBODY SPECIFICITY; BIOLOGICAL TRANSPORT; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALEIMIDES; MICE; MOLECULAR TARGETED THERAPY; PROTEIN TRANSPORT; RECEPTOR, ERBB-2; SINGLE-DOMAIN ANTIBODIES;

EID: 84872266173     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2012.08.008     Document Type: Article

References (41)

1. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001, 2:127-137.
2. Ménard S., Casalini P., Campiglio M., Pupa S., Agresti R., Tagliabue E. HER2 overexpression in various tumor types, focusing on its relationship to the development of invasive breast cancer. Ann Oncol 2001, 12:S15-S19.
3. Scholl S., Beuzeboc P., Pouillart P. Targeting HER2 in other tumor types. Ann Oncol 2001, 12:S81-S87.
4. Hede K. Gastric cancer: trastuzumab trial results spur search for other targets. J Natl Cancer Inst 2009, 101:1306-1307.
5. Metro G., Mottolese M., Fabi A. HER-2-positive metastatic breast cancer: trastuzumab and beyond. Expert Opin Pharmacother 2008, 9:2583-2601.
6. Santin A.D., Bellone S., Roman J.J., McKenney J.K., Pecorelli S. Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. Int J Gynecol Obstet 2008, 102:128-131.
7. Kakar S., Puangsuvan N., Stevens J.M., Serenas R., Mangan G., Sahai S., et al. HER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: comparison of results and correlation with survival. Mol Diagn 2000, 5:199-207.
8. Harmsen M.M., De Haard H.J. Properties, production, and applications of camelid single-domain antibody fragments. Appl Microbiol Biotechnol 2007, 77:13-22.
9. Revets H., De Baetselier P., Muyldermans S. Nanobodies as novel agents for cancer therapy. Expert Opin Biol Ther 2005, 5:111-124.
10. Huang L., Muyldermans S., Saerens D. Nanobodies®: proficient tools in diagnostics. Expert Rev MolDiagn 2010, 10:777-785.
11. Rahbarizadeh F., Ahmadvand D., Sharifzadeh Z. Nanobody; an old concept and new vehicle for immunotargeting. Immunol Invest 2011, 40:299-338.
12. Geissler F., Anderson S.K., Press O. Intracellular catabolism of radiolabeled anti-CD3 antibodies by leukemic T cells. Cell Immunol 1991, 137:96-110.
13. Reist C.J., Garg P.K., Alston K.L., Bigner D.D., Zalutsky M.R. Radioiodination of internalizing monoclonal antibodies using N-succinimidyl 5-iodo-3-pyridine carboxylate. Cancer Res 1996, 56:4970-4977.
14. Reist C.J., Archer G.E., Wikstrand C.J., Bigner D.D., Zalutsky M.R. Improved targeting of an anti-epidermal growth factor receptor variant III monoclonal antibody in tumor xenografts after labeling using N-succinimidyl 5-iodo-3-pyridine carboxylate. Cancer Res 1997, 57:1510-1515.
15. Vaidyanathan G., Affleck D.J., Bigner D.D., Zalutsky M.R. Improved xenograft targeting of tumor-specific anti-epidermal growth factor receptor variant III antibody labeled using N-succinimidyl 4-guanidinomethyl-3-iodobenzoate. Nucl Med Biol 2002, 29:1-11.
16. 131I]SIPMB), a negatively charged substituent bearing acylation agent. Nucl Med Biol 2004, 31:909-919.
17. Foulon C.F., Reist C.J., Bigner D.D., Zalutsky M.R. Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody. Cancer Res 2000, 60:4453-4460.
18. Foulon C.F., Welsh P.C., Bigner D.D., Zalutsky M.R. Positively charged templates for labeling internalizing antibodies: comparison of N-succinimidyl 5-iodo-3-pyridine carboxylate and the D-amino acid peptide KRYRR. Nucl Med Biol 2001, 28:769-777.
19. 1-GEEEK ([*I]IB-Mal-D-GEEEK): a radioiodinated prosthetic group containing negatively charged D-glutamates for labeling internalizing monoclonal antibodies. Bioconjugate Chem 2006, 17:1085-1092.
20. 2 fragment following radioiodination using two different residualizing labels: SGMIB and IB-Mal-D-GEEEK. Nucl Med Biol 2009, 36:671-680.
21. Roovers R.C., Laeremans T., Huang L., De Taeye S., Verkleij A.J., Revets H., et al. Efficient inhibition of EGFR signalling and of tumour growth by antagonistic anti-EGFR nanobodies. Cancer Immunol Immunother 2007, 56:303-317.
22. Yu Z., Xia W., Wang H.Y., Wang S.-C., Pan Y., Kwong K.Y., et al. Antitumor activity of an Ets protein, PEA3, in breast cancer cell lines MDA-MB-361DYT2 and BT474M1. Mol Carcinog 2006, 45:667-675.
23. Lindmo T., Boven E., Cuttitta F., Fedorko J., Bunn P.A. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 1984, 72:77-89.
24. 131I]SIPMB), a negatively charged substituent-bearing acylation agent for the radioiodination of peptides and mAbs. Bioconjugate Chem 2003, 14:331-341.
25. Mume E., Orlova A., Larsson B., Nilsson A.-S., Nilsson F., Sjöberg S., et al. Evaluation of ((4-hydroxyphenyl)ethyl)maleimide for site-specific radiobromination of anti-HER2 affibody. Bioconjugate Chem 2005, 16:1547-1555.
26. Zalutsky M.R., Colcher D., Kaplan W.D., Kufe D.W. Radioiodinated B6.2 monoclonal antibody: further characterization of a potential radiopharmaceutical for the identification of breast tumors. Int J Nucl Med Biol 1985, 12:227-233.
27. Freitas J.E., Gross M.D., Ripley S., Shapiro S. Radionuclide diagnosis and therapy of thyroid cancer: current status report. Semin Nucl Med 1985, 15:106-131.
28. Gainkam L.O.T., Caveliers V., Devoogdt N., Vanhove C., Xavier C., Boerman O., et al. Localization, mechanism and reduction of renal retention of technetium-99m labeled epidermal growth factor receptor-specific nanobody in mice. Contrast Media Mol Imaging 2011, 6:85-92.
29. Vaneycken I., Devoogdt N., Van Gassen N., Vincke C., Xavier C., Wernery U., et al. Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer. FASEB J 2011, 25:2433-2446.
30. Vegt E., De Jong M., Wetzels J.F.M., Masereeuw R., Melis M., Oyen W.J.G., et al. Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med 2010, 51:1049-1058.
31. 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/Micro-CT. J Nucl Med 2008, 49:788-795.
32. 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression. Mol Imaging Biol 2008, 10:167-175.
33. 99mTc to tumor-targeting Affibody molecules. Bioconjugate Chem 2007, 18:549-558.
34. HER2:342, an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors. Bioconjugate Chem 2007, 18:1956-1964.
35. Verrey F., Ristic Z., Romeo E., Ramadan T., Makrides V., Dave M.H., et al. Novel renal amino acid transporters. Annu Rev Physiol 2005, 67:557-572.
36. Rexhepaj R., Grahammer F., Völkl H., Remy C., Wagner C.A., Sandulache D., et al. Reduced intestinal and renal amino acid transport in PDK1 hypomorphic mice. FASEB J 2006, 20:2214-2222.
37. Béhé M., Kluge G., Becker W., Gotthardt M., Behr T.M. Use of polyglutamic acids to reduce uptake of radiometal-labeled minigastrin in the kidneys. J Nucl Med 2005, 46:1012-1015.
38. 177Lu-labeled alpha-melanocyte stimulating hormone peptide analogues. Nucl Med Biol 2006, 33:723-733.
39. 99mTc-labelled Affibody molecules with reduced renal uptake. Eur J Nucl Med Mol Imaging 2008, 35:2245-2255.
40. Mather S.J., McKenzie A.J., Sosabowski J.K., Morris T.M., Ellison D., Watson S.A. Selection of radiolabeled gastrin analogs for peptide receptor-targeted radionuclide therapy. J Nucl Med 2007, 48:615-622.
41. Behr T.M., Becker W.S., Sharkey R.M., Juweid M.E., Dunn R.M., Bair H.-J., et al. Reduction of renal uptake of monoclonal antibody fragments by amino acid infusion. J Nucl Med 1996, 37:829-833.